News headlines about Tokai Pharmaceuticals (NASDAQ:NVUS) have trended somewhat positive on Saturday, according to Accern. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Tokai Pharmaceuticals earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.3800514826408 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of Tokai Pharmaceuticals (NASDAQ:NVUS) remained flat at $3.76 on Friday. The company’s stock had a trading volume of 11,535 shares. Tokai Pharmaceuticals has a 12 month low of $3.42 and a 12 month high of $18.81. The company’s 50-day moving average is $4.76 and its 200-day moving average is $6.08. The company’s market cap is $2.78 million.
Separately, Zacks Investment Research upgraded shares of Tokai Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th.
Novus Therapeutics, Inc, formerly Tokai Pharmaceuticals, Inc, is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities.
What are top analysts saying about Tokai Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tokai Pharmaceuticals Inc. and related companies.